Publication of the OverCool clinical trial protocol – Performance and Safety validation of Vent2Cool in Post Cardiac Arrest Syndrome
The OverCool study represents a world premiere for Total Liquid_Ventilation (TLV), and in the spirit of transparency, we wanted, together with the authors of the protocol, to publish it in the journal Resuscitation Plus.
You can access it for free by clicking on the following link:
Paris, September the 5th, 2024 – Orixha announced that it received the approval from the ANSM (French National Agency for the Safety of Medicines and Health Products) and the Ethics Committee for the OverCool study to be conducted at Hopital Cochin (APHP Paris). The OverCool study aims to achieve two major clinical breakthroughs. First, it will validate the ability to induce therapeutic hypothermia within 2 hours post resuscitation, in order to significantly improve survival and neurological outcomes for cardiac arrest patients. Secondly, the OverCool study will achieve a clinical world premiere for total liquid ventilation as Vent2Cool’s ultra-rapid cooling performance is powered by Orixha’s proprietary lung conservative liquid ventilation technology platform.
The page dedicated to the Luncolive project is now online!
Consult it to find out about the progress of this R&D project on LUNCOLIVE technology funded by the EIC accelerator.
Lyon and Paris, April 10, 2024 – Orixha announces that it has raised 4 million euros from the European Innovation Council Fund and the French Tech Seed fund, managed on behalf of the French government France 2030 initiative by Bpifrance. This financing will enable Orixha to develop and validate in the clinic its total liquid ventilation technology, starting with resuscitated cardiac arrest patients in critical care.
With Luncolive, Orixha aims to promote the Liquid Ventilation as a new breakthrough technology in critical care.
Orixha announces that its Luncolive program has been selected by the European Innovation Council for a founding of 2.5 M€ and a capital investment of 5 M€, in order to improve the survival of post-cardiac arrest patients. This will allow to validate the clinical benefit of the Vent2Cool Solution in post-cardiac arrest syndrome and to explore and developp new medical applications in critical care.
On march 31st, Orixha won the first prize of Innovation at Medi’Nov salon 2022. This competition was organized by the region Auvergne-Rhône-Alpes in France.
Orixha just annonced a foundraising of 2 million euros from Angels Santé, Erganeo and its industrial partners : Infiplast, OEM Development et Activation. This first round will allow to finalize the medical device Vent2Cool before starting the first clinical trial in cardiac arrest patients.
